GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aevi Genomic Medicine Inc (NAS:GNMX) » Definitions » Other Current Assets

Aevi Genomic Medicine (Aevi Genomic Medicine) Other Current Assets : $0.40 Mil (As of Sep. 2019)


View and export this data going back to 2007. Start your Free Trial

What is Aevi Genomic Medicine Other Current Assets?

Aevi Genomic Medicine's other current assets for the quarter that ended in Sep. 2019 was $0.40 Mil.

Aevi Genomic Medicine's quarterly other current assets declined from Mar. 2019 ($0.65 Mil) to Jun. 2019 ($0.57 Mil) and declined from Jun. 2019 ($0.57 Mil) to Sep. 2019 ($0.40Mil).

Aevi Genomic Medicine's annual other current assets increased from Dec. 2016 ($0.34 Mil) to Dec. 2017 ($0.89 Mil) declined from Dec. 2017 ($0.89 Mil) to Dec. 2018 ($0.17 Mil).


Aevi Genomic Medicine Other Current Assets Historical Data

The historical data trend for Aevi Genomic Medicine's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aevi Genomic Medicine Other Current Assets Chart

Aevi Genomic Medicine Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Other Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.32 0.75 0.34 0.89 0.17

Aevi Genomic Medicine Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.54 0.17 0.65 0.57 0.40

Aevi Genomic Medicine Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.


Aevi Genomic Medicine Other Current Assets Related Terms

Thank you for viewing the detailed overview of Aevi Genomic Medicine's Other Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Aevi Genomic Medicine (Aevi Genomic Medicine) Business Description

Traded in Other Exchanges
N/A
Address
435 Devon Park Drive, Suite 715, Wayne, PA, USA, 19087
Medgenics is a clinical-stage biopharmaceutical company involved mainly in genomic medicine. Genomic medicine involves the usage of individual's genomic information to decide upon clinical care. This medical discipline is used in the fields of oncology, pharmacology, rare and undiagnosed diseases, and infectious diseases. Medgenics' partner is the Center for Applied Genomics at the Children's Hospital of Philadelphia, with which it works to develop drugs by implementing genomics medicine.
Executives
Michael F Cola director, officer: Chief Executive Officer 435 DEVON PARK BUILDING 800, WAYNE PA 19087-1945
Sol J Barer director C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Barbara Gayle Duncan director C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES STREET, NEW YORK NY 10013
Garry Arthur Neil officer: Chief Scientific Officer 555 CALIFORNIA STREET, SUITE 365, SAN FRANCISCO CA 94104
Eugene A Bauer director C/O APPLIED UV, INC., 150 N. MACQUESTEN PKWY, MOUNT VERNON NY 10550
Alastair J Clemow director C/O APPLIED UV, INC., 150 N. MACQUESTEN PKWY, MOUNT VERNON NY 10550
Grano Joseph J Jr director C/O MEDGENICS, INC., 435 DEVON PARK DRIVE BLDG 700, WAYNE PA 19087
Plc Astrazeneca 10 percent owner 1 FRANCIS CRICK AVENUE, CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE X0 CB2 0AA
Brian Piper officer: CFO & Corporate Secretary C/O MEDGENICS, INC., 435 DEVON PARK DRIVE, BLDG. 700, WAYNE PA 19087
Wilbur H Gantz director C/O MEDGENICS, INC., 435 DEVON PARK DRIVE BLDG 700, WAYNE PA 19087
Scott Applebaum officer: Chief Legal Officer C/O TREVENA INC., 955 CHESTERBROOK BOULEVARD, SUITE 110, CHESTERBROOK PA 19087
Isaac Blech director C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Joel S Kanter director C/O APPLIED UV, INC., 150 N. MACQUESTEN PKWY, MOUNT VERNON NY 10550
John Harold Leaman officer: Chief Financial Officer 555 CALIFORNIA STREET, SUITE 365, SAN FRANCISCO CA 94104
Clarence L Dellio officer: Chief Operating Officer 435 DEVON PARK DRIVE BLDG 700, C/O MEDGENICS, INC., WAYNE PA 19087